ND BioSciences is developing proprietary platforms, technologies, reagents and tools to enable the discovery and validation of novel biochemical and imaging biomarkers and both antibody and small molecule therapies. Our powerful proprietary technologies and innovative tools enable for the first time reproducing, at both the biochemical and structural levels, the proteoforms and pathological species found in the brain and biological fluids of patients suffering from neurodegenerative diseases.
These unique capabilities combined into integrated platforms with our ongoing efforts to develop innovative and proprietary tools place us in a very competitive position to 1) discover and validate novel biomarkers and targets; 2) develop imaging agents that capture the pathological diversity of neurodegenerative diseases; 3) develop sensitive and accurate assays for early diagnosis, monitoring disease progression and to support human clinical trials and precision medicine in neurodegenerative diseases.
The technologies, model systems and platforms of ND-BioSciences are based on more than 20 years of groundbreaking research by its founder, Prof. Hilal Lashuel and enable the company to take more holistic and innovative approaches to develop desperately needed diagnostics and therapies for neurodegenerative diseases.
Unlike most competing companies, which focus on detecting of targeting one specific form of the disease-causing proteins, ND BioSciences diagnostic and therapeutic approaches are based on capturing the diversity of their proteoforms and pathological diversity and on targeting the processes that are essential to neurodegeneration and pathology formation and spreading in the brain.